ALKEM Q4 Results FY26 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated May 27, 2026 3 min read

Alkem Laboratories enters its Q4 FY26 earnings print as a leader in the acute pharmaceutical segment, balancing strong domestic volume growth against the high capital requirements of its emerging MedTech and CDMO ventures. Investors will be focused on the company's margin trajectory following recent labour-code impacts and the operational scaling of its new manufacturing facilities.

Quick Details

Results date	May 28, 2026
Quarter	Q4
Previous quarter revenue	Rs. 3,736.8 crore
Previous quarter PAT	Rs. 636.0 crore
Previous quarter EBITDA margin	22.2%
Market cap	Rs. 64,879.78 Cr
CMP	Rs. 5,424.05

ALKEM Q4 Results Date and Time

The board meeting is scheduled for May 28, 2026, to consider the audited financial results and recommend a final dividend for FY2026.

The conference call for the Q4FY26 and FY26 results is scheduled for May 20, 2026.

What to expect from ALKEM's Q4 FY26 results

Alkem continues to leverage its domestic leadership, having outperformed the Indian Pharmaceutical Market in both acute and chronic segments during the previous quarter. Management has guided for a low double-digit growth of 10% to 11% for the US business in FY26, supported by a pipeline of 188 ANDA filings and recent approvals. The company is actively managing the integration of its MedTech and CDMO segments, which are currently incurring combined losses of approximately Rs. 125 crore annually before reaching breakeven. Investors will likely look for updates on the Ujjain facility, where the planned investment was recently revised upward to Rs. 1,036 crore.

Key Things To Watch

Performance vs Guidance Tracking

Domestic Growth — Outperform IPM by 100 to 150 basis points — On track
US Business Growth — 10% to 11% for FY26 — On track
EBITDA Margin — Flat 19.5% to 20% for FY26 — On track
R&D Spend — Within 5% of revenue — On track

Strategic Execution and Capex Updates

Ujjain greenfield facility investment increased by 94.37% to Rs. 1,036 crore
Occlutech acquisition of majority stake for EUR 180.70 million expected to complete by June 30, 2026
MedTech segment targeting 10% market share by 2028 with Knee launch in Q2 FY27 and Hip launch in Q4 FY27

Risks and Headwinds to Monitor

Disputed income tax assessment order for AY 2023-24 totaling Rs. 333.38 crore
Mirabegron launch delayed due to ongoing litigation settlement
Combined operating losses from US CDMO plant and MedTech business estimated at Rs. 125 crore

Frequently Asked Questions

What is the status of the Alkem MedTech business breakeven?

Management has projected MedTech losses of Rs. 40-50 crore in both FY26 and FY27. The company is aiming for a breakeven in FY28.

How is the US CDMO facility at Enzene performing?

The plant started operations in September 2025 and generates Rs. 15-20 crore in revenue per quarter. Management aims for an annual run-rate of Rs. 300 crore over the next 12 to 18 months.

What is the update on the Occlutech acquisition?

Alkem has made a binding offer to acquire a majority stake in Occlutech for approximately Rs. 1,074 crore. The transaction is expected to be completed by June 30, 2026.